Work

A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity

Year: 2009

Type: article

Source: Vaccine

DOI: 10.1016/j.vaccine.2009.09.127

Authors: Rich-Henry Schabowsky, Kutlu G. Elpek, Shravan Madireddi, Rajesh K. Sharma, Esma S. Yolcu, Laura Bandura-Morgan, Robert Miller, Kathryn J. MacLeod, Robert S. Mittler, Haval Shirwan

Institutions: University of Louisville, ApoVax (United States), Emory University

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute, National Institute of Allergy and Infectious Diseases

Awards: ApoVax104-HPV as a Novel Vaccine for Cervical Cancer, ApoVax104-HPV as a Novel Vaccine for Cervical Cancer, ApoVax-SVN as a Novel Vaccine for Cancer Immunotherapy, ApoVax104-TB as a Novel Vaccine for Tuberculosis

OpenAlex ID: W1992005224

FWCI: 2.035

Cites: 50

Cited by: 54

Related to: 10